Oncology · Lung CancerTrial Updateclinicalmid-term

Pilot Study on Immune Response After SABR in Stage I NSCLC

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 6:31:49 AM

Assessment confidence: 78% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

This pilot study could significantly influence treatment strategies for stage I non-small cell lung cancer (NSCLC) by elucidating the immune response post-SABR. Positive outcomes may lead to the development of combination therapies that enhance patient outcomes, making it crucial for pharma strategy teams to stay informed on the results. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 16 ranked evidence items (12 high-relevance).

Strategic Assessment

Positive findings may support the development of combination therapies that enhance immune response post-radiation. The strongest clinical anchor is Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (sidney kimmel comprehensive cancer center). In lung cancer, 4 regulatory and 4 competitive items passed relevance filtering for Sidney Kimmel Comprehensive Cancer Center.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sub-indication match (lung cancer); sponsor/company relevance (roche). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. The study could provide insights into the immunogenic effects of SABR, potentially influencing treatment strategies in lung cancer.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Positive findings may prompt regulatory interest in new treatment combinations, influencing approval pathways and labeling for existing therapies in the lung cancer space.

Key Risks

Elevated medium regulatory exposure for Sidney Kimmel Comprehensive Cancer Center could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the study demonstrates a strong immune response, it could lead to new combination therapies that capture market share in the oncology sector, potentially increasing revenue for companies involved in lung cancer treatments.
Upside for Sidney Kimmel Comprehensive Cancer Center may improve if Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Sidney Kimmel Comprehensive Cancer Center may improve if Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.

What Would Change This Assessment

This becomes more urgent if Monitor results from TCR sequencing and immune response assays for potential implications on treatment protocols.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (sidney kimmel comprehensive cancer center)
FDA document
View source
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With PD-L1 Expression < 1% or
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Novartis)
FDA document
View source
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer)
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise
Humanexa Signalshigh relevance
Sub-indication match (lung cancer)

Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sidney Kimmel Comprehensive Cancer Center
stage I NSCLC treatment protocols
SABR therapy

Commercial impact

medium

If the study demonstrates a strong immune response, it could lead to new combination therapies that capture market share in the oncology sector, potentially increasing revenue for companies involved in lung cancer treatments.

Regulatory impact

medium

Positive findings may prompt regulatory interest in new treatment combinations, influencing approval pathways and labeling for existing therapies in the lung cancer space.

What to watch

Monitor results from TCR sequencing and immune response assays for potential implications on treatment protocols.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.